The invention relates to conjugates comprising a targeting moiety specific for the CXCR4 based on the polyphemusin derived peptide and a therapeutic or imaging agent. The invention relates as well to the application of said conjugates for the therapy and diagnostics which require the specific targeting to CXCR4+ cells.